SNDX Q2 2022 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$38M

Net Income

-$38M

EPS (Diluted)

$-0.62

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$40M

Free Cash Flow

-$40M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$406M

Total Liabilities

$44M

Stockholders' Equity

$362M

Cash & Equivalents

$120M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$379,000	-100.0%
Gross Profit	$0	$379,000	-100.0%
Operating Income	-$38M	-$22M	-68.9%
Net Income	-$38M	-$23M	-64.0%